Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 369 results:
Συντάκτης [ Τίτλος(Desc)] Τύπος Έτος
Φίλτρα: Συντάκτης is Polyzos, Stergios A  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
N
Kountouras, J., Zavos C., Deretzi G., Polyzos S. A., Gavalas E., Tsiaousi E., et al. (2011).  Neuroprotection in glaucoma: is there a future role of Helicobacter pylori eradication?. Exp Eye Res. 92(5), 436-8.
Anastasilakis, A. D., Goulis D. G., Polyzos S. A., Gerou S., Ballaouri I., Efstathiadou Z., et al. (2009).  No difference between strontium ranelate (SR) and calcium/vitamin D on bone turnover markers in women with established osteoporosis previously treated with teriparatide: a randomized controlled trial.. Clin Endocrinol (Oxf). 70(4), 522-6.
Makras, P., Anastasilakis A. D., Polyzos S. A., Bisbinas I., Sakellariou G. T., & Papapoulos S. E. (2011).  No effect of rosuvastatin in the zoledronate-induced acute-phase response.. Calcif Tissue Int. 88(5), 402-8.
Polyzos, S. A., Kountouras J., Anastasilakis A. D., Makras P., Hawa G., Sonnleitner L., et al. (2018).  Noggin levels in nonalcoholic fatty liver disease: the effect of vitamin E treatment.. Hormones (Athens). 17(4), 573-579.
Polyzos, S. A., & Mantzoros C. S. (2016).  Nonalcoholic fatty future disease.. Metabolism. 65(8), 1007-16.
Polyzos, S. A., & Kountouras J. (2023).  Nonalcoholic fatty liver disease and Helicobacter pylori infection. Is it time to address this potential relationship?. Curr Vasc Pharmacol.
Polyzos, S. A., Chrysavgis L., Vachliotis I. D., Chartampilas E., & Cholongitas E. (2023).  Nonalcoholic fatty liver disease and hepatocellular carcinoma:Insights in epidemiology, pathogenesis, imaging, prevention and therapy.. Semin Cancer Biol. 93, 20-35.
Vachliotis, I. D., Anastasilakis A. D., Goulas A., Goulis D. G., & Polyzos S. A. (2022).  Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implications.. Diabetes Obes Metab. 24(9), 1702-1720.
Polyzos, S. A., Goulis D. G., & Kountouras J. (2015).  Nonalcoholic fatty liver disease and polycystic ovary syndrome.. Ann Hepatol. 14(6), 941-3.
Polyzos, S. A., Mousiolis A., Mintziori G., & Goulis D. G. (2020).  Nonalcoholic fatty liver disease in males with low testosterone concentrations.. Diabetes Metab Syndr. 14(5), 1571-1577.
Polyzos, S. A., Goulis D. G., Kountouras J., Mintziori G., Chatzis P., Papadakis E., et al. (2014).  Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis.. Hormones (Athens). 13(4), 519-31.
Paschou, S. A., Polyzos S. A., Anagnostis P., Goulis D. G., Kanaka-Gantenbein C., Lambrinoudaki I., et al. (2019).  Nonalcoholic fatty liver disease in women with polycystic ovary syndrome.. Endocrine.
Polyzos, S. A., Kountouras J., Anastasiadis S., Doulberis M., & Katsinelos P. (2018).  Nonalcoholic fatty liver disease: Is it time for combination treatment and a diabetes-like approach?. Hepatology. 68(1), 389.
Vachliotis, I., Goulas A., Papaioannidou P., & Polyzos S. A. (2021).  Nonalcoholic fatty liver disease: lifestyle and quality of life.. Hormones (Athens).
Polyzos, S. A., Kountouras J., Zavos C., & Deretzi G. (2012).  Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease.. J Clin Gastroenterol. 46(4), 272-84.
Polyzos, S. A., Papaefthymiou A., Doulberis M., & Kountouras J. (2023).  Nonalcoholic fatty liver disease test: an external validation cohort.. Hormones (Athens).
Polyzos, S. A., Kountouras J., & Zavos C. (2009).  Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines.. Curr Mol Med. 9(3), 299-314.
Athyros, V. G., Polyzos S. A., Kountouras J., Katsiki N., Anagnostis P., Doumas M., et al. (2019).  Non-alcoholic fatty liver disease treatment in patients with type 2 diabetes mellitus; new kids on the block.. Curr Vasc Pharmacol.
Polyzos, S. A., Bugianesi E., Kountouras J., & Mantzoros C. S. (2017).  Nonalcoholic fatty liver disease: Updates on associations with the metabolic syndrome and lipid profile and effects of treatment with PPAR-γ agonists.. Metabolism. 66, 64-68.
Perakakis, N., Polyzos S. A., Yazdani A., Sala-Vila A., Kountouras J., Anastasilakis A. D., et al. (2019).  Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: a proof of concept study.. Metabolism. 154005.
Polyzos, S. A., Slavakis A., Koumerkeridis G., Katsinelos P., & Kountouras J. (2019).  Noninvasive Liver Fibrosis Tests in Patients with Nonalcoholic Fatty Liver Disease: An External Validation Cohort.. Horm Metab Res. 51(2), 134-140.
Polyzos, S. A., Anastasilakis A. D., Anagnostis P., Kita M., Arsos G., Moralidis E., et al. (2012).  Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid.. Endokrynol Pol. 63(4), 312-5.
Anastasilakis, A. D., Savvides M., Polyzos S. A., Georgopoulos C., & Delaroudis S. (2010).  Normochromic normocytic anemia in a postmenopausal woman with severe osteoporosis treated with intermittent parathyroid hormone.. J Bone Miner Metab. 28(1), 108-10.
Polyzos, S. A., & Kountouras J. (2015).  Novel Advances in the Association Between Helicobacter pylori Infection, Metabolic Syndrome, and Related Morbidity.. Helicobacter. 20(6), 405-9.
Kazakos, E. I., Kountouras J., Polyzos S. A., & Deretzi G. (2017).  Novel aspects of defensins' involvement in virus-induced autoimmunity in the central nervous system.. Med Hypotheses. 102, 33-36.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές